Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | See "Remarks" | May 13, 2024 | May 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 13, 2024 · Filed May 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-13 · Sale · Disposed 15,219 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.74 to $16.76, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.74 to $16.76, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2024 Filed May 15, 2024 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 15,219 | $16.74 | $254,807.15 |
DisclosureSEC source: 0000950170-24-060065 · ownership.xml · nonDerivative · entry 1 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.74 to $16.76, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,954 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-027973 · ownership.xml · derivative · entry 3 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,957 Underlying: Ordinary Shares · 4,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 4,954 vesting on March 5, 2024, and 4,957 vesting on March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 4,954 vesting on March 5, 2024, and 4,957 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,427 | $13.52 | $19,286.48 |
DisclosureSEC source: 0000950170-24-027973 · ownership.xml · nonDerivative · entry 2 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,219 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,954 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-027973 · ownership.xml · nonDerivative · entry 1 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 33,482 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026098 · ownership.xml · derivative · entry 7 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,482 Underlying: Ordinary Shares · 33,482 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 8,370 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 8,372 vesting on March 4, 2028. F8 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 8,370 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 8,372 vesting on March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 7,117 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026098 · ownership.xml · derivative · entry 6 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,237 Underlying: Ordinary Shares · 7,117 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 7,117 vesting on each of March 4, 2024 and March 4, 2025, and 7,120 vesting on March 4, 2026. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 7,117 vesting on each of March 4, 2024 and March 4, 2025, and 7,120 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,042 | $13.37 | $27,308.28 |
DisclosureSEC source: 0000950170-24-026098 · ownership.xml · nonDerivative · entry 4 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,692 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 7,117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026098 · ownership.xml · nonDerivative · entry 3 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,490 | $13.37 | $19,926.22 |
DisclosureSEC source: 0000950170-24-026098 · ownership.xml · nonDerivative · entry 2 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,617 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026098 · ownership.xml · derivative · entry 5 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,538 Underlying: Ordinary Shares · 5,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:39 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026098 · ownership.xml · nonDerivative · entry 1 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023520 · ownership.xml · derivative · entry 3 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 4,294 vested on February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 4,294 vested on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,366 | $13.12 | $17,916.46 |
DisclosureSEC source: 0000950170-24-023520 · ownership.xml · nonDerivative · entry 2 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,928 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.19, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 11:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,294 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-023520 · ownership.xml · nonDerivative · entry 1 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 12:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 33,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055447 · doc4.xml · derivative · entry 1 Conway Vikki L · CIK 0001995297 · See "Remarks" 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,482 Underlying: Ordinary Shares · 33,482 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on November 15, 2023, with 8,370 vesting on each of November 15, 2024, November 15, 2025 and November 15, 2026, and 8,372 vesting on November 15, 2027. F2 · derivative.expiration_date: Restricted share units were granted on November 15, 2023, with 8,370 vesting on each of November 15, 2024, November 15, 2025 and November 15, 2026, and 8,372 vesting on November 15, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.